Yes, mood stabilizers and antidepressants can be taken together, and in many cases the combination is specifically recommended. This pairing is most common in bipolar depression, where antidepressants alone can destabilize mood, and in treatment-resistant depression, where a mood stabilizer is added to boost an antidepressant that isn’t working well enough on its own. The combination does require more monitoring than either drug alone, and not every pairing works the same way.
Why the Two Are Often Prescribed Together
The most straightforward reason is bipolar disorder. People with bipolar depression spend far more time in depressive episodes than manic ones, and antidepressants can help with those lows. But taking an antidepressant without a mood stabilizer in bipolar disorder carries a real risk of triggering a manic or hypomanic episode. Antidepressant treatment increases the odds of a manic switch by roughly 70% compared to not using one. In continuation trials, where the antidepressant is kept going beyond the initial treatment phase, switch rates climb to 33% or higher. A mood stabilizer acts as a guardrail, reducing that risk.
Current treatment guidelines recommend antidepressants only as add-on therapy to a mood stabilizer or atypical antipsychotic in bipolar depression, not as standalone treatment. This applies especially to people with Bipolar I disorder, those with rapid cycling, mixed features, or a history of becoming destabilized on antidepressants. One large study following over 1,100 bipolar patients for a year found a 61% rate of mood conversion during antidepressant therapy, underscoring why the mood stabilizer component matters.
For Bipolar II, the picture is a bit different. Some controlled trials suggest that antidepressant monotherapy can work in Bipolar II with a relatively low manic switch rate. But a chart-review study found that even in Bipolar II, switch rates were higher with antidepressant monotherapy than with the combination. The research is still mixed because many studies lump Bipolar I and II patients together.
The Combination for Treatment-Resistant Depression
If you have unipolar depression (no bipolar diagnosis) and your antidepressant isn’t providing enough relief, your prescriber may add a mood stabilizer rather than switch medications entirely. This strategy is called augmentation, and lithium is the best-studied option for it.
Lithium augmentation roughly doubles the odds of responding to treatment compared to placebo. In head-to-head comparisons, lithium has a better risk-to-benefit ratio than adding a second-generation antipsychotic or esketamine. For every five patients who try lithium augmentation, about one will achieve remission who wouldn’t have otherwise. That number (called the “number needed to treat”) compares favorably: for antipsychotic augmentation, it takes about 11 patients to get one additional remission.
Lithium augmentation is particularly recommended for people with recurrent depressive episodes (more than three), significant slowing of movement and thinking, unexplained weight loss, or elevated suicide risk. In these groups, the evidence for benefit is strongest.
What About Lamotrigine?
Lamotrigine is a mood stabilizer widely used for bipolar maintenance, and you might expect it to pair well with SSRIs for depression. The actual data is less encouraging. A meta-analysis of three studies testing lamotrigine added to SSRIs like fluoxetine and paroxetine found no significant benefit over placebo for acute unipolar depression. Lamotrigine’s primary strength is preventing future depressive episodes in bipolar disorder rather than treating a current one, so its role in combination therapy is more about long-term stability than acute relief.
How Long It Takes to Work
Patience matters with this combination. In a large study tracking 590 people with bipolar depression on mood-stabilizing treatment, about a third had not responded after two weeks, but nearly half of those non-responders eventually responded by 24 weeks. Among people still not improved at six weeks (a common benchmark for an adequate trial), only about one in three went on to respond by six months, and roughly 29% achieved remission.
These numbers suggest that if you’re not feeling better after six to eight weeks on the combination, the odds of that specific regimen working drop considerably. That’s typically the point where a prescriber will reassess the plan.
Serotonin Syndrome Risk
One safety concern specific to combining these drug classes is serotonin syndrome, a potentially dangerous condition caused by too much serotonin activity in the brain. Lithium increases serotonin-related signaling, and SSRIs do the same by a different mechanism. Valproic acid (another common mood stabilizer) is also listed among drugs that can contribute to serotonin syndrome. Combining any of these with an SSRI or SNRI raises the theoretical risk.
Serotonin syndrome is uncommon, but it’s worth knowing the early signs: agitation, restlessness, rapid heartbeat, muscle twitching, and diarrhea. In severe cases, it can cause high fever and seizures. The risk increases most when doses are raised or a new serotonin-affecting medication is added. Carbamazepine, another mood stabilizer sometimes used off-label, also appears on the list of drugs that can contribute.
Monitoring and Blood Work
Taking both drug classes together generally means more lab work than taking an antidepressant alone, because mood stabilizers require regular blood level checks and organ function testing.
- Lithium requires baseline kidney function tests, thyroid panels (T3, T4, and TSH), calcium levels, a urinalysis, and an EKG before starting. Blood lithium levels are checked regularly, with the target range for augmentation therapy typically between 0.5 and 0.8 mEq/L. For adults 65 and older, the target is usually kept below 0.6. Lithium can affect the thyroid and parathyroid glands over time, so those labs continue throughout treatment.
- Valproic acid requires liver function tests before starting, because it can cause serious liver damage in rare cases. These are repeated periodically to catch problems early.
Antidepressants on their own rarely need blood monitoring (with a few exceptions), so if you’re used to just taking a daily pill without lab visits, expect that to change when a mood stabilizer is added.
Weight Gain and Side Effects
Weight gain is one of the most common concerns with this combination. Many mood stabilizers, particularly lithium and valproic acid, can cause weight gain on their own. Adding an antidepressant (some of which also affect weight) can compound the issue. When more than one medication is involved, the likelihood of gaining weight goes up simply because each drug contributes its own metabolic effects.
Other common side effects of the combination include tremor, nausea, gastrointestinal discomfort, and sedation. Lithium specifically can cause increased thirst and urination. Over the long term, lithium use is associated with effects on the kidneys and thyroid, which is why ongoing monitoring is necessary. These side effects don’t affect everyone, and they’re often manageable with dose adjustments, but they’re worth weighing against the benefits, especially if the combination is intended as a long-term strategy.
Short-Term Versus Long-Term Use
Most guidelines recommend that when antidepressants are used alongside mood stabilizers for bipolar depression, they should be kept as short-term additions rather than permanent fixtures. The concern is that prolonged antidepressant use in bipolar disorder can accelerate the frequency of mood episodes or induce rapid cycling, where a person swings between depression and mania more often than they otherwise would.
For unipolar treatment-resistant depression, the calculus is different. Lithium augmentation is often maintained for at least a year, and some evidence supports keeping it going indefinitely if it’s working, particularly because lithium has a well-documented effect on reducing suicide risk and preventing relapse. The decision to continue or taper either medication depends on how stable your mood has been and what happened during previous attempts to reduce treatment.